Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARSUN: Mosunetuzumab-Lenalidomide vs Investigator Choices in R/R MZL
NCT06006117Phase 3Recruiting
- Sponsor
- LYSARC
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of mosunetuzumab in marginal zone lymphoma (MZL), sponsored by LYSARC. Started Sep 2023; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06006117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006117.